Role of Mid-induction Peripheral Blood Minimal Residual Disease Detection in Pediatric B-Lineage Acute Lymphoblastic Leukemia.
To study the role of mid-induction (day 15) peripheral blood minimal residual disease (PB-MRD) detection in pediatric B- lineage acute lymphoblastic leukemia (B-ALL). Prospective. Tertiary-care center. 40 consecutively-diagnosed treatment-naive, pediatric B-ALL patients. National Cancer Institute (NCI) standard risk patients were given three drug induction regimen comprising vincristine, L-asparginase and prednisolone; NCI high-risk patients were supplemented with daunorubicin. Day 15 PB-MRD and bone marrow MRD (BM-MRD) analyzed by six color flow cytometry. The sensitivity of day 15 PB-MRD to identify concurrent day 15 BM-MRD positivity was 64%, with 100% specificity. The positive and negative predictive values were 100% and 62.5%, respectively. PB-MRD was positive in 67% of relapsed patients. BM-MRD is a well-established prognostic factor in B-ALL. We suggest, day 15 PB-MRD could be considered as an early, minimally invasive and easily accessible MRD screening option.